Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare neurodegenerative disorder characterised by variability in both age of onset and clinical features. Despite the recent identification of the CAG expansion mutation in DRPLA, the number of molecularly confirmed cases remains small. Given its rarity and prominent phenotypic heterogeneity, some care needs to be exercised in the interpretation and dissemination of test results derived from direct gene testing for the DRPLA specific expansion mutation.
Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder with a clinically heterogeneous phenotype. Core clinical features include myoclonus, epilepsy, ataxia, choreiform movements, and dementia/mental retardation. Associated findings can include psychiatric disease and subcortical white matter changes. Although originally described in kindreds of Japanese descent,'2 the recent identification and subsequent molecular confirmation of DRPLA in families outside Japan underscores the probability of a wider geographical and ethnic distribution.`6 The molecular defect in DRPLA involves the expansion of an unstable (CAG),. repeat within a recently characterised gene on the short arm of chromosome 12.7 In general, there is a statistically significant correlation between (CAG)n repeat length, clinical phenotype, and ages of onset with the largest repeats associated with the juvenile onset form of the disease.89 However, for any given repeat length, age of onset can be variable. While repeat length alone accounts for approximately 50 to 68% of the variability,89 the other factors involved in this variability are currently unknown. Possible mechanisms in-clude the influences of mitotic instability of disease alleles in various tissues, sequence variations in the 5' and 3' regions of the DRPLA gene, trans acting effects of the normal gene product, or other genetic/environmental factors. As this expansion mutation has been found in all DRPLA patients studied to date,`6 the analysis of (CAG),, repeat number should serve as a highly accurate diagnostic and predictive test for this disease. At present, this test is useful to the physician seeking confirmation of a clinical diagnosis of DRPLA or when DRPLA is part of the differential diagnosis of a neurodegenerative or movement disorder. Of equal importance is the use of testing for predictive purposes. However, it must be stressed that its prognostic value is limited to modifying the a priori risk of inheriting a DRPLA allele. It does not provide any diagnostic information regarding the current status of the patient nor a prediction regarding age of onset of clinical symptoms. This latter point is extremely important as the association between (CAG),, and age of onset in individual families may be variable."8 The following case report provides an illustration.
The pedigree is presented in fig 1. The relevant clinical histories of patients III-14, IV-26, and IV-27 and the methodology used to determine allele sizes have been described previously.5 IV-28, a 24 year old female who was recently evaluated, presented with a six year history of emotional lability, a generalised seizure disorder, mild ataxia, and dementia. Her mother's clinical course was that of a gradual mental deterioration and psychiatric disease (hallucinations and delusions), ataxia, and seizures over a nine year period. Her maternal grandfather (II-10) had an onset of psychiatric symptoms in his 20s and motor involvement in his early 30s. He was totally disabled by the age of 41. A seizure disorder was diagnosed at 53 years. He died at the age of 58. In general, there was an inverse correlation between (CAG), repeat number and age of onset among those family members tested.5 However, direct comparisons ofDRPLA allele sizes from several The relationship between (CAG) repeat number and age of onset in a family with dentatorubral-pallidoluysian atrophy (DRPLA) 11 L24 @51 L6 (7 L8 . Variation in DRPLA allele size family.5 was small. At most, there was a change of four What are the molecular diagnostic im-CAG repeats among these four patients, despite plications of this intrafamilial variability? Priman age of onset that ranged from 33 in III14 arily it needs to be recognised that significant to 7 in IV-27 (age 21 in IV-26, 18 in IV-28). differences in age of onset can be associated More striking was the demonstration of a sim-with no, or minimal increase in repeat ilar number of repeats for III-14, IV-26, and length '89 and, as evident with the molecular IV-28 despite a 15 year difference in the onset genotyping of our family, very little prognostic information could have been inferred if the testing was predictive in nature. Furthermore, 114 IV26 IV27 IV.28
as the DNA used for such analyses is derived from leucocytes, it should be noted that tissue specific instability (somatic mosaicism) has been reported for this disorder.10 Therefore A(CAG)I -(CAG)5 wcaution must be exercised in the interpretation of test results. Second, like Huntington's disease, DRPIA is frequently associated with psychiatric symp-toms9 which have been reported as the presenting feature in several families."' In our kindred, neuropsychiatric disturbances were common; III 18 was diagnosed as schizophrenic and his father II-1O carried a diagnosis of an organic brain syndrome with psychosis. III-14 suffered from visual and auditory hallucinations and III-20 and IV-28 were diagnosed with personality disorders. Anecdotally, both IIIE14 and IV-27 initially presented with subtle behavioural/personality alterations de- , as examples of adult onset neurodegenerative diseases for which diagnostic and predictive testing is available. Direct gene testing for DRPLA is clearly useful to confirm or exclude a diagnosis in a patient with suggestive symptoms, particularly those with a family history of an autosomal dominant neurodegenerative disorder. However, given the significant inter/intrafamilial phenotypic heterogeneity, variable age of onset, and prominent neuropsychiatric sequelae, it remains imperative that guidelines similar to those established for predictive testing for HD"6 be used in testing for this rare neurodegenerative disorder. confirmatory and predictive testing. 
